Beta Bionics prices $150M public offering at $17.25/share

Beta Bionics Inc. (NASDAQ: BBNX) has priced a public offering of 7.65 million shares at $17.25 per share, as reported by a press release. The company also offered pre-funded warrants to purchase 1.04 million shares at a slightly lower price of $17.2499 to select investors. Gross proceeds from the offering are projected to reach $150 million, not including underwriting discounts, commissions, and offering expenses.

The sale is set to close around September 17, 2026, depending on various conditions. Beta Bionics has the option to purchase an additional 1.3 million shares within a 30-day window at the same price, less fees. The funds raised are expected to be utilized for general corporate purposes, potentially covering costs related to the commercialization of their iLet Bionic Pancreas, expansion of manufacturing, research and development, clinical trials, investments in product enhancements, strategic opportunities, working capital, and operating expenses.

Major banks J.P. Morgan, Piper Sandler, Wells Fargo Securities, and Leerink Partners are managing the offering. The shares and warrants are part of a shelf registration statement filed with the SEC on February 24, 2026, and became effective upon submission. Beta Bionics is a commercial-stage medical device company specializing in insulin delivery devices for individuals with diabetes, with its iLet Bionic Pancreas being the first FDA-cleared autonomous insulin delivery device.